AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Von Hippel-Lindau Disease

Recent research efforts aimed at curing Von Hippel-Lindau Disease.

Last updated

Von Hippel-Lindau Disease

Overview

Von Hippel-Lindau disease (VHL) is a rare inherited cancer-predisposition syndrome caused by a harmful change in the VHL tumor-suppressor gene. It is usually inherited in an autosomal-dominant pattern, meaning that each child of an affected person has a 50% chance of inheriting the altered gene. VHL can cause tumors and cysts in several organs, including clear-cell kidney cancer, tumors of the brain and spinal cord called hemangioblastomas, retinal hemangioblastomas that can threaten vision, pheochromocytomas, pancreatic cysts and neuroendocrine tumors, and inner-ear tumors that can affect hearing and balance. GeneReviews overview (ncbi.nlm.nih.gov)

Prognosis varies widely because the number, location, and growth rate of lesions differ among people and families. Current care is therefore lifelong surveillance plus organ-preserving treatment—such as surgery, ablation, laser therapy, or selective tumor removal—when a lesion becomes dangerous. For adults with VHL-associated renal cell carcinoma, central-nervous-system hemangioblastomas, or pancreatic neuroendocrine tumors that do not need immediate surgery, the HIF-2α inhibitor belzutifan is now a standard systemic option; it treats tumors but does not correct the inherited VHL variant. GeneReviews management VHL surveillance guideline (ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has been highly active, but it has largely concentrated on preventing or shrinking VHL-associated tumors rather than repairing the inherited gene in every at-risk cell. The central question has been whether blocking hypoxia-inducible factor 2-alpha (HIF-2α)—a protein that becomes abnormally active when VHL function is lost—can replace repeated surgery and preserve organ function. Belzutifan established that this pathway is clinically actionable, while laboratory programs are testing more selective RNA delivery, synthetic-lethal targets, and improved models of VHL-deficient tumors. A true genetic cure remains preclinical and is not close to routine clinical use. LITESPARK-004 50-month follow-up VHL therapeutic opportunities (pmc.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

The major clinical breakthrough has been HIF-2α inhibition with belzutifan, an oral small molecule that blocks an important cancer-driving consequence of VHL loss rather than restoring the VHL gene itself. In the original phase 2 LITESPARK-004 study, belzutifan produced an objective response in 49% of participants with VHL-associated renal cell carcinoma after a median 21.8 months of follow-up; activity was also observed in pancreatic lesions and central-nervous-system hemangioblastomas. Initial LITESPARK-004 report (pubmed.ncbi.nlm.nih.gov)

Longer follow-up strengthened that result. At a median 49.9 months in LITESPARK-004, 67% of the 61 participants had an objective response in VHL-associated renal cell carcinoma, including seven complete responses, and 92% had some reduction in the summed diameters of renal target lesions. This durability matters because repeated kidney operations can progressively reduce kidney function; however, continued tumor control on a drug is not equivalent to eliminating the underlying inherited disease. LITESPARK-004 50-month follow-up NCI renal natural-history study (pmc.ncbi.nlm.nih.gov)

For neurologic disease, a dedicated analysis of LITESPARK-004 reported that belzutifan had meaningful and sustained antitumor activity in VHL-associated central-nervous-system hemangioblastomas for more than three years. This is especially important for people whose tumors are multiple, surgically difficult to reach, or likely to require repeated procedures over a lifetime. CNS hemangioblastoma analysis (pubmed.ncbi.nlm.nih.gov)

Several experimental strategies aim to improve on pathway inhibition. One RNA-therapy approach used CD70-targeted micelles—tiny drug-delivery particles—to carry small interfering RNA against HIF2A into patient-derived clear-cell renal-carcinoma cells. The system reduced HIF-2α and downstream cancer-promoting signals in cell experiments, but it has not yet been established as a treatment for people with inherited VHL disease. CD70-targeted HIF2A siRNA study (pubmed.ncbi.nlm.nih.gov)

Other preclinical studies are identifying vulnerabilities beyond direct HIF-2α blockade. For example, inhibiting the iron-sulfur-cluster protein ISCA2 lowered HIF proteins and triggered ferroptosis—an iron-dependent form of cell death—in VHL-deficient renal-cancer models, including tumor xenografts. These approaches may eventually help address drug resistance, but they remain laboratory-stage cancer strategies rather than cures for germline VHL disease. ISCA2 and ferroptosis study (pubmed.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

The pivotal VHL-specific study is LITESPARK-004 (NCT03401788), a Merck-sponsored, single-arm phase 2 trial of belzutifan in adults with VHL-associated renal cell carcinoma and other VHL lesions. It is ongoing but no longer recruiting, and its 50-month analysis provides the strongest long-term evidence that systemic HIF-2α inhibition can delay or reduce the need for local procedures in selected adults. LITESPARK-004 50-month follow-up (pmc.ncbi.nlm.nih.gov)

Long-term treatment questions are now being addressed through LITESPARK-043 (NCT07405164), a recruiting phase 3 extension study sponsored by Merck Sharp & Dohme. The study enrolls participants from selected prior belzutifan trials, including people with VHL-related tumors, to evaluate longer-term efficacy and safety; its estimated primary completion date is January 14, 2034. LITESPARK-043 registry record (clinicaltrials.gov)

No clinical gene-replacement or gene-editing treatment has yet demonstrated that it can safely correct the inherited VHL alteration throughout relevant tissues. Instead, current experimental work uses gene editing mainly to create better disease models. A 2024 study used kidney-directed viral delivery of CRISPR guide RNAs in mice to disable Vhl together with additional tumor-suppressor genes, producing tumors that partially resembled human clear-cell renal cancer and responded to axitinib. CRISPR Vhl-deficient mouse model (pubmed.ncbi.nlm.nih.gov)

Methodologies and Scientific Approaches

VHL researchers combine longitudinal imaging studies, germline genetic testing, tumor sequencing, patient-derived cells, and animal models. National Cancer Institute natural-history programs track lesion growth, surgical outcomes, genotype-phenotype relationships, and renal function over time; these data help distinguish a genuine treatment effect from the variable natural behavior of VHL tumors. NCI inherited-urologic-cancer protocol NCI renal natural-history study (cancer.gov)

At the laboratory level, researchers model VHL loss in engineered cells, patient-derived tumor cultures, xenografts, and increasingly in immunocompetent CRISPR-engineered mice. These platforms are used to test HIF-2α suppression, tumor-targeted RNA delivery, metabolic dependencies, ferroptosis, and mechanisms of resistance before therapies can move toward human trials. CRISPR Vhl-deficient mouse model CD70-targeted HIF2A siRNA study ISCA2 and ferroptosis study (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

Major clinical and translational contributors include the U.S. National Cancer Institute, which operates long-running VHL and inherited-kidney-cancer natural-history protocols; the University of Texas MD Anderson Cancer Center and Massachusetts General Hospital, whose investigators led key LITESPARK-004 work; and the multi-country network of academic centers participating in that study. Merck developed and sponsors belzutifan clinical research. NCI inherited-urologic-cancer protocol LITESPARK-004 50-month follow-up (cancer.gov)

Patient-led funding is also important in this small field. The VHL Alliance reports more than $3 million in research grants awarded since its founding and currently lists a $25,000 one-year pilot grant, a $100,000 two-year research grant, and $100,000 over two years for postdoctoral fellowships. Its recent grant-recipient list includes investigators at the University of Freiburg, Francis Crick Institute, University of Utah, UCLA, MD Anderson, and other VHL-focused institutions. VHL Alliance research grants (vhl.org)

Strengths, Limitations, and Challenges

The clearest strength of recent research is that it translated a precise biological insight—excess HIF-2α signaling after VHL loss—into an effective oral therapy with durable, multi-organ activity. Belzutifan can reduce tumor burden and may postpone surgeries that carry cumulative risks to kidney function, neurologic function, vision, hearing, and quality of life. LITESPARK-004 50-month follow-up CNS hemangioblastoma analysis (pmc.ncbi.nlm.nih.gov)

However, belzutifan is disease control, not a cure: it does not repair the germline VHL variant, eliminate all tumor-prone cells, or remove the need for surveillance. Treatment can also cause on-target anemia because HIF-2α contributes to erythropoietin regulation, and hypoxia, fatigue, dose modifications, affordability, access, long-term adherence, tumor resistance, and uncertainty about the safest duration of therapy remain practical challenges. Initial LITESPARK-004 report GeneReviews management (pubmed.ncbi.nlm.nih.gov)

Outlook and Future Directions

As of October 1, 2026, VHL research is closer to durable medical control of several tumor manifestations than to a one-time cure. The most important milestones to watch are longer-term LITESPARK-004 and LITESPARK-043 results; evidence on whether belzutifan safely prevents surgeries over many years; biomarkers that predict response or resistance; and progress in tumor-targeted RNA, synthetic-lethal, and ultimately gene-restoration approaches. A curative therapy will likely require safe, durable correction or compensation for VHL loss across multiple at-risk organs, a much more difficult goal than shrinking existing tumors. LITESPARK-043 registry record VHL therapeutic opportunities (clinicaltrials.gov)

References

Don't see your disease? Request a report